Neurosense Therapeutics Ltd (NRSN)

Jun 17, 2025

NeuroSense Therapeutics (NRSN) Expected to Announce Earnings on Tuesday - Defense World

Jun 17, 2025

Jun 12, 2025

Why It Makes Sense To Keep An Eye On NeuroSense Therapeutics - RTTNews

Jun 12, 2025

Jun 09, 2025

Jane Street Group LLC Makes New Investment in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World

Jun 09, 2025

Jun 06, 2025

Top Nasdaq Companies by Market Cap Ranked by Kalkine - Kalkine Media

Jun 06, 2025

Jun 06, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Trading Up 1.2% – Here’s What Happened - Defense World

Jun 06, 2025

Jun 06, 2025

Citadel Advisors LLC Buys 219,717 Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World

Jun 06, 2025

Jun 04, 2025

NRSNNeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - mx.advfn.com

Jun 04, 2025

Jun 02, 2025

NRSN stock touches 52-week high at $1.65 amid robust gains - Investing.com

Jun 02, 2025

May 21, 2025

NRSN stock touches 52-week high at $1.52 amid growth optimism - Investing.com Australia

May 21, 2025

May 14, 2025

D. Boral Capital Begins Coverage on NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World

May 14, 2025

May 13, 2025

D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation - Nasdaq

May 13, 2025

May 12, 2025

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsNeuroSense Therapeutics (NASDAQ:NRSN) - Benzinga

May 12, 2025

May 12, 2025

Boral Capital starts NeuroSense stock with Buy, $14 target By Investing.com - Investing.com South Africa

May 12, 2025

May 12, 2025

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga

May 12, 2025

May 12, 2025

NeuroSense (NRSN) Receives Buy Rating with Promising Outlook | N - GuruFocus

May 12, 2025

May 12, 2025

Boral Capital starts NeuroSense stock with Buy, $14 target - Investing.com

May 12, 2025

May 09, 2025

Amyotrophic Lateral Sclerosis Market Set for Groundbreaking - openPR.com

May 09, 2025

May 07, 2025

NeuroSense Completes PrimeC Manufacturing Scale-Up for Canadian Launch - TipRanks

May 07, 2025

May 07, 2025

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch - Nasdaq

May 07, 2025

May 06, 2025

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - ADVFN

May 06, 2025

May 05, 2025

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - ADVFN

May 05, 2025

Apr 30, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why - Defense World

Apr 30, 2025

Apr 24, 2025

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership - TipRanks

Apr 24, 2025

Apr 24, 2025

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - Quantisnow

Apr 24, 2025

Apr 23, 2025

Head-To-Head Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) versus TFF Pharmaceuticals (NASDAQ:TFFP) - Defense World

Apr 23, 2025

Apr 16, 2025

NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine

Apr 16, 2025

Apr 09, 2025

Neurosense Therapeutics Announces Phase 2B Microrna Data - marketscreener.com

Apr 09, 2025

Apr 09, 2025

Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan

Apr 09, 2025

Apr 09, 2025

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - PR Newswire

Apr 09, 2025

Apr 08, 2025

NeuroSense Therapeutics Reports 2024 Financial Results - TipRanks

Apr 08, 2025

Apr 08, 2025

NeuroSense Therapeutics Reports 2024 Financial Results and Advances ALS Treatment - MSN

Apr 08, 2025

Apr 07, 2025

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates - The Malaysian Reserve

Apr 07, 2025

Apr 04, 2025

NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN

Apr 04, 2025

Apr 04, 2025

Breakthrough ALS Treatment Shows Disease-Modifying Results in Phase 2b Trial - Stock Titan

Apr 04, 2025

Apr 04, 2025

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting - PR Newswire

Apr 04, 2025

Mar 31, 2025

Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com

Mar 31, 2025

Mar 27, 2025

NeuroSense Updates on Pharmaceutical Partnership Discussions - TipRanks

Mar 27, 2025

Mar 25, 2025

Amyotrophic Lateral Sclerosis Pipeline: Advancing the Future with 50+ Innovators Leading Breakthrough Therapies - openPR.com

Mar 25, 2025

Mar 24, 2025

Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth - Business Wire

Mar 24, 2025

Mar 24, 2025

Motor Neuron Disease Clinical Pipeline | 180+ Companies Advancing Next-Generation Therapies - openPR.com

Mar 24, 2025

Mar 22, 2025

NeuroSense Therapeutics (NRSN) to Release Earnings on Monday - Defense World

Mar 22, 2025

Mar 21, 2025

NeuroSense Therapeutics: A Promising Biotech Stock in the Neurodegenerative Space - eng.expertclub.ge

Mar 21, 2025

Mar 20, 2025

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug - Business Wire

Mar 20, 2025

Mar 19, 2025

NeuroSense Advances PrimeC Commercialization in Canada - TipRanks

Mar 19, 2025